hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing

Journal of Clinical Investigation

Volumn 120, Issue 11, 2010, Pages 3923-3939

  Goehe, Rachel Wilson ^a   Shultz, Jacqueline C ^a   Murudkar, Charuta ^a   Usanovic, Sanja ^a   Lamour, Nadia F ^a   Massey, Davis H ^a   Zhang, Lian ^b   Camidge, D Ross ^b   Shay, Jerry W ^c   Minna, John D ^c   Chalfant, Charles E ^a,d,e  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; CASPASE 9A; CASPASE 9B; HETEROGENOUS NUCLEAR RIBONUCLEOPROTEIN L; MESSENGER RNA; SERINE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; RNA PROCESSING; TUMOR XENOGRAFT;

ALTERNATIVE SPLICING; ANIMALS; CASPASE 9; CELL LINE, TUMOR; EXONS; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN L; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; RNA PRECURSORS; RNA, SMALL INTERFERING; SILENCER ELEMENTS, TRANSCRIPTIONAL; TRANSPLANTATION, HETEROLOGOUS;

EID: 78049448047     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI43552     Document Type: Article

References (42)

1. Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis. 2004;9(6):691-704.
2. Kominsky DJ, Bickel RJ, Tyler KL. Reovirus-induced apoptosis requires both death receptor- and mitochondrial- mediated caspase-dependent pathways of cell death. Cell Death Differ. 2002;9(9):926-933. (Pubitemid 35023608)
3. Liang Q, et al. 6-Hydroxydopamine induces dopaminergic cell degeneration via a caspase-9-mediated apoptotic pathway that is attenuated by caspase-9dn expression. J Neurosci Res. 2004;77(5):747-761.
4. Philchenkov A, Zavelevich M, Kroczak TJ, Los M. Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp Oncol. 2004;26(2):82-97. (Pubitemid 44253087)
5. Seol DW, Billiar TR. A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis. J Biol Chem. 1999;274(4):2072-2076. (Pubitemid 29061358)
6. Srinivasula S M, et al. Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis. Cancer Res. 1999;59(5):999-1002.
7. Stephanou A, Scarabelli TM, Knight RA, Latchman DS. Antiapoptotic activity of the free caspase recruitment domain of procaspase-9: a novel endogenous rescue pathway in cell death. J Biol Chem. 2002;277(16):13693-13699.
8. Wu GS, Ding Z. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene. 2002;21(1):1-8.
9. Yacoub A, et al. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther. 2004;3(8):739-751.
10. Soengas MS, et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science. 1999;284(5411):156-159.
11. Ebert AD, Chen F, He X, Cryns VL, Bohn MC. A tetracycline-regulated adenovirus encoding dominant-negative caspase-9 is regulated in rat brain and protects against neurotoxin-induced cell death in vitro, but not in vivo. Exp Neurol. 2005; 191 suppl 1:S80-S94.
12. Hakem R, et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell. 1998;94(3):339-352.
13. Cheng C, Sharp PA. Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol Cell Biol. 2006;26(1):362-370.
14. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 2007;14(3):185-193.
15. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell. 2009;33(5):591-601.
16. Siebert PD, Larrick JW. Competitive PCR. Nature. 1992;359(6395):557-558.
17. Chalfant CE, et al. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem. 2002;277(15):12587-12595.
18. Kole R. Modification of pre-mRNA splicing by antisense oligonucleotides. Acta Biochim Pol. 1997;44(2):231-237.
19. Patel NA, et al. The protein kinase C beta II exon confers mRNA instability in the presence of high glucose concentrations. J Biol Chem. 2003;278(2):1149-1157.
20. Taylor JK, Zhang QQ, Wyatt JR, Dean NM. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol. 1999;17(11):1097-1100.
21. Scott CL, et al. Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation. J Cell Biol. 2004;164(1):89-96.
22. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res. 2003;31(13):3568-3571.
23. Koscielny G, et al. ASTD: The alternative splicing and transcript diversity database. Genomics. 2009;93(3):213-220.
24. Hui J, Reither G, Bindereif A. Novel functional role of CA repeats and hnRNP L in RNA stability. RNA. 2003;9(8):931-936.
25. Shih SC, Claffey KP. Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J Biol Chem. 1999;274(3):1359-1365.
26. Taguchi F, et al. hnRNP L enhances sensitivity of the cells to KW-2189. Int J Cancer. 2004;108(5):679-685.
27. Melton AA, Jackson J, Wang J, Lynch KW. Combinatorial control of signal-induced exon repression by hnRNP L and PSF. Mol Cell Biol. 2007;27(19):6972-6984.
28. Yu J, Hai Y, Liu G, Fang T, Kung S K, Xie J. The heterogeneous nuclear ribonucleoprotein L is an essential component in the Ca2+/calmodulin-dependent protein kinase IV-regulated alternative splicing through cytidine-adenosine repeats. J Biol Chem. 2009;284(3):1505-1513.
29. Sui S, et al. Phosphoproteome analysis of the human Chang liver cells using SCX and a complementary mass spectrometric strategy. Proteomics. 2008;8(10):2024-2034.
30. Keshava Prasad TS, et al. Human Protein Reference Database - 2009 update. Nucleic Acids Res. 2009; 37(Database issue):D767-D772.
31. Obenauer JC, Cantley LC, Yaffe MB. Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res. 2003;31(13):3635-3641.
32. UniProt Consortium. The Universal Protein Resource (UniProt) 2009. Nucleic Acids Res. 2009;37(Database issue):D169-D174.
33. Massiello A, Chalfant CE. SRp30a (ASF/SF2) regulates the alternative splicing of caspase-9 premRNA and is required for ceramide-responsiveness. J Lipid Res. 2006;47(5):892-897.
34. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell. 2002;1(3):289-298.
35. Ekert PG, et al. Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die. J Cell Biol. 2004;165(6):835-842.
36. Chipuk JE, Green DR. Do inducers of apoptosis trigger caspase-independent cell death? Nat Rev Mol Cell Biol. 2005;6(3):268-275.
37. Senft J, Helfer B, Frisch SM. Caspase-8 interacts with the p85 subunit of phosphatidylinositol 3- kinase to regulate cell adhesion and motility. Cancer Res. 2007;67(24):11505-11509.
38. Motta-Mena LB, Heyd F, Lynch KW. Context-dependent regulatory mechanism of the splicing factor hnRNP L. Mol Cell. 2010;37(2):223-234.
39. Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 2008;68(7):2358-2365.
40. Sato M, et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res. 2006;66(4):2116-2128. (Pubitemid 43294921)
41. Office of Laboratory Animal Welfare. Public health service policy on humane care and use of laboratory animals [policy]. 2002. http://grants.nih.gov/ grants/olaw/references/phspol.htm.
42. Office of Science and Technology Policy. U.S. Government principles for the utilization and care of vertebrate animals used in testing, research and training. Federal Register. 1985;50(97).